Beckman Coulter Life Sciences transforms purification with the launch of the OptiMATE Gradient Maker
Beckman Coulter Life Sciences has launched the OptiMATE Gradient Maker, an automated density gradient ultracentrifugation system designed to significantly reduce purification workflow times by up to 75%. This new instrument aims to improve consistency, reproducibility, and efficiency in laboratories, particularly for applications like viral vector purification for research use. The system simplifies complex gradient preparation, reducing manual steps and extensive training requirements, and will be debuted at the American Society of Gene & Cell Therapy (ASGCT) in May 2025.
Insider Selling: Danaher (NYSE:DHR) EVP Sells 1,320 Shares of Stock
Danaher (NYSE:DHR) EVP Gregory Milosevich sold 1,320 shares of the company's stock on February 19th, reducing his stake by 20.56%. The shares were sold at an average price of $208.01, totaling $274,573.20. Despite the insider selling, analysts maintain a "Moderate Buy" rating for Danaher with an average price target of $253.86, and the company recently reported strong quarterly earnings, beating EPS and revenue estimates.
Top Analyst Reports for Philip Morris, Lockheed Martin & Danaher
This article summarizes the latest analyst reports on Philip Morris (PM), Lockheed Martin (LMT), and Danaher (DHR), highlighting their recent performance, growth drivers, and challenges. Philip Morris benefits from smoke-free products but faces regulatory pressure; Lockheed Martin gains from defense contracts despite labor shortages; and Danaher sees growth in biotechnology but is impacted by high debt and forex issues. Additionally, a microcap stock, Zeo Energy (ZEO), is discussed, noting its underperformance but potential for margin expansion through improved pricing and acquisitions.
Former Cytiva CEO Emmanuel Ligner Takes Helm at Avantor: 30-Year Industry Veteran to Drive Growth
Avantor has announced the appointment of Emmanuel Ligner as its new President and CEO, effective August 18, 2025. Ligner brings over 30 years of experience in the life sciences industry, including leadership roles at GE Life Sciences and as CEO of Cytiva and Cerba HealthCare. His appointment is expected to drive competitive growth across Avantor's Lab Solutions and Bioscience Production divisions.
Top Analyst Reports for Philip Morris, Lockheed Martin & Danaher
Zacks Investment Research has released new analyst reports on 16 major stocks, including Philip Morris International (PM), Lockheed Martin Corp. (LMT), and Danaher Corp. (DHR), along with micro-cap Zeo Energy Corp. (ZEO). The reports provide analysis on their recent performance, growth drivers, and potential challenges. Philip Morris benefits from smoke-free products, Lockheed Martin from defense contracts, and Danaher from its bioprocessing and diagnostics segments, while Zeo Energy is entering an earnings inflection phase despite risks.
Resmed Founder to Receive Prestigious Award
Peter Craig Farrell, founder of ResMed, will receive the 2026 Horatio Alger Award for his accomplishments despite challenges and his commitment to higher education. Farrell founded ResMed in 1989, a global provider of medical devices for sleep apnea, and established the Farrell Family Foundation in 2001. He will be inducted alongside 10 other honorees in Washington, DC, in April.
Medtronic to cut 81 employees at California diabetes site
Medtronic (NYSE:MDT) is laying off 81 employees at its Northridge, California diabetes device facility, effective April 7, 2026. This restructuring comes as the company prepares to spin out its diabetes business, MiniMed, into a standalone public entity. The affected roles include engineering, IT, marketing, and technician positions, with Medtronic stating the cuts are necessary to ensure the new company's long-term success.
Rx Rundown: Danaher, Johnson & Johnson, Bayer and more
This article provides an "Rx Rundown" summarizing significant medical marketing news, deal-making, and industry chatter from the previous week. Key highlights include Danaher's acquisition of Masimo for $9.9 billion, Madrigal Pharmaceuticals' $4.4 billion licensing deal, multiple FDA approvals and rejections, notable funding rounds, and industry news such as Bayer's $7.25 billion Roundup settlement and Johnson & Johnson's expansion and paused clinical trials.
A Look At Avantor (AVTR) Valuation After A Year Of Weak Shareholder Returns
Avantor (AVTR) has experienced a significant share price decline over the past year, resulting in a negative shareholder return and a low value score. Despite this, a common narrative suggests the stock is undervalued by about 43% with a fair value of $13.04, driven by growth in biologics and personalized medicine. However, potential risks like weaker bioprocessing demand and elevated leverage could challenge this undervalued thesis, prompting investors to conduct their own analysis.
Halper Sadeh LLC is Investigating Whether VRME, MASI, VAL are Obtaining Fair Deals for their Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating VerifyMe, Inc. (VRME), Masimo Corporation (MASI), and Valaris Limited (VAL) for potential violations of federal securities laws and breaches of fiduciary duties. The firm is concerned that insiders may receive substantial benefits and that proposed transactions could limit superior offers. Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options regarding these transactions.
Charles River Laboratories NYSE CRL Quarterly Profit Streak Tests Bearish Profitability Narrative
Charles River Laboratories International (CRL) recently reported its FY 2025 third-quarter numbers, showing a revenue of US$1,004.9 million and EPS of US$1.11, moving away from a previous net loss. The company has posted three consecutive quarters of positive net income in FY 2025, contrasting with a trailing 12-month net loss of US$83.5 million. While analysts expect continued growth and a return to profitability over the next three years, skeptics note that the trailing 12-month EPS remains a loss and historical losses have widened, suggesting the recovery is still in its early stages.
Danaher to Acquire Masimo in Transaction Valued at $9.9 Billion
Danaher Corporation has entered into a definitive agreement to acquire Masimo Corporation for $180 per share in cash, valuing the transaction at approximately $9.9 billion. Masimo, known for its pulse oximetry and patient monitoring technologies, will operate as a standalone company within Danaher’s Diagnostics segment upon closing. The acquisition is expected to enhance Danaher’s diagnostic capabilities and generate over $530 million in EBITDA for Masimo by 2027.
Masimo's Board Backs Danaher's $9.9B Cash Acquisition Proposal
Masimo's board has unanimously approved a definitive agreement to be acquired by Danaher for $9.9 billion in cash, with Danaher offering $180 per Masimo share. The acquisition is expected to close in the second half of 2026 and will see Masimo operate as a standalone unit within Danaher’s Diagnostics segment, enhancing Danaher's acute care portfolio. This deal follows a period where Masimo explored various opportunities, including a significant drop in share price after controversial acquisitions and an ongoing patent lawsuit with Apple.
Ontario Teachers Pension Plan Board Purchases New Stake in Thermo Fisher Scientific Inc. $TMO
The Ontario Teachers Pension Plan Board has acquired a new stake of 23,798 shares in Thermo Fisher Scientific Inc. (NYSE:TMO), valued at approximately $11.54 million, during the third quarter. The company recently reported strong quarterly earnings, beating analyst estimates with $6.57 EPS and $12.22 billion in revenue, and its board approved a $5.00 billion share buyback program. Analyst sentiment for Thermo Fisher Scientific is generally positive, with a "Moderate Buy" consensus rating and an average price target of $633.68.
IDEXX Stock Has Rallied 40% Over the Past Year: Can a New CEO Keep the Momentum Going?
IDEXX Laboratories recently announced Michael Erickson will succeed Jay Mazelsky as CEO, following a year where shares surged significantly. Despite beating Q4 revenue estimates, concerns arose from a guided 2% decline in U.S. same-store clinical visits, causing a slight stock dip. Analysts project a potential 38% upside to $873 by December 2028, contingent on sustained 9% revenue growth and 33% operating margins, though the exit multiple already aligns with current market pricing.
$19.8 Billion Cell and Gene Therapy Tools & Reagents Market Outlook, 2030 Featuring Thermo Fisher Scientific, Cytiva (Danaher), Merck, Miltenyi Biotec, Sartorius and More
The global market for cell and gene therapy tools and reagents is projected to reach $19.8 billion by 2030, growing at a CAGR of 10.6% from $12 billion in 2025. This growth is driven by increasing clinical and commercial activities in cell and gene therapies (CGTs), significant R&D investments, and regulatory approvals for novel CGTs. The market report provides comprehensive insights into segmentation by product type, application, and end-user, profiling key players such as Thermo Fisher Scientific, Cytiva (Danaher), Merck, Miltenyi Biotec, and Sartorius.
Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Masimo Corporation - MASI
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Masimo Corporation (NasdaqGS: MASI) to Danaher Corporation (NYSE: DHR) for $180.00 per share in cash. The law firm is examining whether this consideration and the process leading to the transaction adequately value Masimo. Shareholders who believe the Company is undervalued are encouraged to contact KSF to discuss their legal rights.
Masimo Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Masimo Corporation - MASI
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Masimo Corporation to Danaher Corporation for $180.00 cash per share. KSF aims to determine if this price and the sale process are adequate or if the company is undervalued. The law firm is inviting Masimo shareholders to contact them to discuss their legal rights regarding the proposed transaction.
GE HealthCare, BARDA ink $35M expansion to AI-enabled imaging deal
GE HealthCare has secured a $35 million contract expansion from the U.S. government's Biomedical Advanced Research and Development Authority (BARDA) to further develop AI-enabled ultrasound technology for trauma care. This builds on a prior 2023 agreement and aims to create tools that allow non-expert users to more easily and quickly diagnose patients, particularly in demanding environments. The expanded project focuses on improving assessments of lung pathologies and intra-abdominal injuries, with GE HealthCare co-funding the initiative, although BARDA provides the majority of the funds.
Wells Fargo & Company Reaffirms "Equal Weight" Rating for Masimo (NASDAQ:MASI)
Wells Fargo & Company has reiterated an "Equal Weight" rating for Masimo (NASDAQ:MASI) and adjusted its price target to $180, down from $190, following news of Danaher's acquisition offer for $180 per share. The medical equipment provider's stock, currently trading around $175.36, is receiving a consensus "Hold" rating from analysts with an average price target of $181.17. The acquisition, valued at approximately $9.9 billion, is expected to close in the second half of 2026, though potential regulatory and litigation risks could cause delays.
Danaher buys patient monitoring specialist Masimo in $9.9B deal
Danaher Corporation has announced the acquisition of Masimo, a patient monitoring medtech company, for $9.9 billion. Masimo will operate as a standalone company within Danaher's diagnostics segment, strengthening Danaher's portfolio with advanced sensor technology and AI-enabled monitoring. This acquisition follows a period of challenges for Masimo, including a proxy fight and a legal battle with Apple over patent infringement, and is expected to accelerate growth for Danaher’s diagnostics segment.
Masimo (MASI) Climbs 34% on $9.9-Billion Danaher Merger
Masimo Corporation (MASI) saw its shares jump over 34% after announcing a definitive agreement to be acquired by Danaher Corporation for $9.9 billion, or $180 per share. The acquisition price represents a 38.3% premium over Masimo's closing price on February 13. Masimo will continue to operate as a standalone business unit within Danaher’s Diagnostics segment upon the transaction's expected closing in the second half of the year.
Danaher Corporation to Acquire Masimo Corporation
Danaher Corporation is set to acquire Masimo Corporation for approximately $9.9 billion, a strategic move aimed at strengthening Danaher's diagnostics and real-time care capabilities with Masimo's advanced sensor and AI-enabled technologies. This acquisition positions Danaher to enhance integrated clinical workflows, leverage large-scale physiological datasets for predictive models, and play a central role in the evolving AI-enabled healthcare market. The deal, expected to close in late 2026, reflects a broader industry shift towards connected platforms that combine diagnostics, monitoring, and analytics to deliver more efficient and personalized patient care.
Are MASI, KW, VRME, BKKT Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating Masimo Corporation (MASI), Kennedy-Wilson Holdings, Inc. (KW), VerifyMe, Inc. (VRME), and Bakkt Holdings, Inc. (BKKT) regarding potential violations of federal securities laws and breaches of fiduciary duties. The firm is concerned that insiders may receive unfair benefits in proposed transactions for these companies, potentially at the expense of ordinary shareholders. Halper Sadeh LLC encourages shareholders to contact them to discuss their legal rights and options.
Danaher Corp to acquire Masimo for $9.9B
Danaher Corp announced its acquisition of Masimo Corp for $9.9 billion, including debt, at $180 per share. This move aims to strengthen Danaher's diagnostics portfolio with Masimo's leadership in pulse oximetry and patient monitoring solutions. The acquisition is expected to be accretive to Danaher’s earnings and generate significant synergies, with the transaction anticipated to close in the second half of 2026.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of
Brodsky & Smith LLC is investigating potential breaches of fiduciary duties by the boards of Masimo Corporation (MASI), IHS Holding Limited (IHS), VerifyMe, Inc. (VRME), and Great Lakes Dredge & Dock Corporation (GLDD). These investigations stem from recent merger agreements, with the firm questioning whether the deals provide fair value to shareholders and if the boards conducted fair processes. Shareholders are encouraged to contact the firm to discuss these investigations without financial obligation.
Danaher to buy Masimo for $9.9B to boost diagnostics portfolio
Danaher has announced its agreement to acquire patient monitoring company Masimo for $9.9 billion to enhance its diagnostics portfolio. Masimo will operate as a standalone business unit within Danaher's diagnostics segment, contributing to high-single-digit core revenue growth long-term. The acquisition, approved by both boards, is expected to close in the second half of 2026 pending regulatory approvals.
Masimo to Be Acquired by Danaher in Merger
Masimo Corporation has agreed to be acquired by Danaher Corporation in an all-cash merger valued at $9.9 billion, or $180 per share. The deal, unanimously approved by both boards, will see Masimo become a standalone business unit within Danaher’s Diagnostics segment and its shares delisted from Nasdaq. The transaction, expected to close in the second half of 2026, aims to consolidate patient-monitoring technologies within Danaher's larger diagnostics portfolio.
Masimo to Be Acquired by Danaher in $180-Per-Share All-Cash Merger
Masimo announced it will be acquired by Danaher for $180.00 per share in an all-cash merger, making Masimo a wholly-owned subsidiary. The transaction requires Masimo stockholder approval, regulatory clearances, and other conditions, with Politan Capital Management already agreeing to vote its shares in favor. Upon completion, Masimo shares will be delisted from Nasdaq.
Danaher Agrees to Buy Medical Tech Firm Masimo for $9.9 Billion
Danaher Corp. has agreed to acquire medical technology firm Masimo Corp. for approximately $9.9 billion, paying $180 per share in cash. This acquisition, which represents a nearly 40% premium over Masimo's closing share price on Friday, will allow Danaher to expand its presence in the medical supply business. The deal is anticipated to close in the second half of the current year.
Gas Chromatography Systems Market to Reach US$7.20 Billion
The global Gas Chromatography Systems Market is projected to reach US$7.20 billion by 2032, growing at an 8.8% CAGR from 2025 to 2032, up from US$3,668.75 million in 2024. This growth is driven by increasing demand for advanced analytical instrumentation in various sectors like environmental analysis, pharmaceuticals, and food safety, with North America leading the market. Key players like Thermo Fisher Scientific, Agilent Technologies, and Shimadzu Corporation are advancing the market through technological innovations in detector sensitivity, automation, AI integration, and the development of portable systems.
Masimo agrees to $9.9B cash sale to Danaher at $180/share | DHR Stock News
Masimo Corporation announced it has entered into a definitive agreement to be acquired by Danaher Corporation for $180.00 per share in cash, totaling $9.9 billion. The acquisition, unanimously approved by both boards, will see Masimo operate as a standalone business unit within Danaher's Diagnostics segment. The transaction is expected to close in the second half of 2026 and aims to strengthen Danaher's patient monitoring offerings while providing significant value to Masimo shareholders.
Danaher to buy Masimo for $9.9 billion
Danaher will acquire pulse oximeter maker Masimo in a $9.9 billion deal, aiming to strengthen its diagnostics portfolio. This acquisition marks Danaher's largest deal since 2023 and is expected to expand its presence in patient-monitoring products, complementing its existing medical devices. The deal is anticipated to close by the second half of 2026 and contribute to Danaher's adjusted diluted net earnings per share.
US Premarket Movers: Danaher, Fiserv, General Mills, Masimo, Zim
This article highlights key premarket stock movers in the US, including Danaher, Fiserv, General Mills, Masimo, and Zim. It notes that S&P 500 Index futures are down, and investors are focused on identifying stocks benefiting from the artificial intelligence trend at the start of a shortened trading week.
Danaher reportedy nears $10B deal to buy Masimo
Danaher (NYSE: DHR) is reportedly close to acquiring Masimo (Nasdaq: MASI) in a deal valued at approximately $9.9 billion, with an announcement potentially coming as early as today, February 17, 2026. This acquisition would significantly expand Danaher's digital health and patient monitoring capabilities, adding Masimo's pulse oximeters and healthcare monitoring systems. The potential deal comes after a turbulent period for Masimo, including a CEO resignation, layoffs, a refocus on healthcare technology, and ongoing legal battles with Apple.
Seabridge Gold Overhauls Finance Leadership Ahead of CFO Retirement
Seabridge Gold is undergoing a significant leadership change in its finance department as CFO Chris Reynolds is set to retire on March 31, 2026. Greg Martin will succeed Reynolds as CFO, with Hassan Esmaeili promoted to VP Finance, aiming to strengthen the team for anticipated joint venture plans on its KSM project. This restructuring prepares Seabridge Gold for a transition from project development to becoming an operating producer.
Leidos beats on earnings but misses revenue expectations, shares fall
Leidos Holdings, Inc. (NYSE:LDOS) exceeded analyst expectations for fourth-quarter adjusted earnings per share but fell short on revenue. Despite a 16% YoY increase in EPS and strong net bookings, shares declined in pre-market trading, primarily due to lower-than-anticipated revenue attributed to an extra work week in FY24 and a government shutdown in FY25. The company provided fiscal year 2026 guidance, projecting revenue and adjusted EPS generally in line with analyst estimates, and announced the acquisition of power design firm Entrust.
Danaher is expected to pay $180 per share in cash for Masimo - WSJ
Danaher is reportedly set to acquire medical technology company Masimo for $180 per share in cash, a deal estimated to be around $10 billion. The acquisition, confirmed by the Wall Street Journal, is expected to be officially announced on Tuesday. This noticia follows earlier reports of Danaher closing in on a significant deal for Masimo.
Danaher Nears $9.9 Billion Acquisition of Masimo Corp.
Danaher is reportedly close to acquiring Masimo for $9.9 billion, a significant premium over Masimo's market cap, with an announcement possibly coming as early as Tuesday. This move follows Masimo's governance changes influenced by activist investors and has led to a 5.22% fall in Danaher's premarket shares while Masimo's surged 34.51%. The acquisition aims to strengthen Danaher's position in the medical technology sector.
Danaher Corporation $DHR Position Increased by HighTower Advisors LLC
HighTower Advisors LLC significantly increased its stake in Danaher Corporation ($DHR) by 20.4% in the third quarter, bringing its total holdings to 408,649 shares valued at approximately $81.02 million. This increase follows Danaher's strong quarterly performance, which beat EPS and revenue estimates, and aligns with generally positive analyst ratings, with a "Moderate Buy" consensus and an average price target of $253.86. The article also notes other institutional investors adjusting their positions and details Danaher's recent dividend announcement.
Why Is Masimo Stock Skyrocketing Tuesday? - Danaher (NYSE:DHR), Masimo (NASDAQ:MASI)
Masimo's stock surged over 34% after reports emerged that Danaher is close to acquiring the medical device maker for approximately $9.9 billion. This potential deal follows significant changes in Masimo's governance, initiated by activist investors, and comes after challenges related to strategic missteps and a patent dispute with Apple. The acquisition would represent a notable premium over Masimo's recent market capitalization.
Crestwood Advisors Group LLC Sells 12,970 Shares of Danaher Corporation $DHR
Crestwood Advisors Group LLC reduced its stake in Danaher Corporation (NYSE:DHR) by 3.9% in the third quarter, selling 12,970 shares. The firm now holds 316,651 shares worth $62.78 million, making Danaher its 26th largest holding. Other institutional investors have also adjusted their positions in the company.
Danaher to buy Masimo in $9.9 billion deal in diagnostics push
Danaher announced its intent to acquire Masimo, a pulse oximeter maker, for $9.9 billion to bolster its diagnostics portfolio. The deal, priced at $180 per share, represents a significant premium for Masimo shareholders. This acquisition is Danaher's largest since 2023 and is expected to expand its presence in patient-monitoring products.
Masimo Heads For $10B Buyout After Winning Blood Oxygen Patent Case Against Apple
Med-tech firm Masimo is reportedly nearing a $10 billion buyout by Danaher Corp. following its successful patent infringement case against Apple regarding blood oxygen monitoring technology. Masimo, which recently underwent an organizational realignment and sold its consumer audio business, had a market capitalization of $7 billion last Friday. The deal would mark another significant acquisition for Danaher, which has been expanding its healthcare portfolio.
Danaher Nears $10 Billion Acquisition of Masimo
Danaher (DHR) is reportedly close to acquiring Masimo (MASI) for approximately $10 billion, a move that would significantly bolster Danaher's position in the medical technology sector. This acquisition, if finalized, would be Danaher's largest since its $21.4 billion purchase of Cytiva, showcasing its continued investment in biotechnology. Despite a recent decline in Masimo's stock, this deal is expected to provide Danaher with new growth opportunities given the sustained demand for medical devices.
Danaher nears $10B acquisition of medical tech company Masimo, FT reports (DHR:NYSE)
Danaher Corporation (DHR) is reportedly close to acquiring medical technology company Masimo (MASI) in a deal valued at approximately $10 billion. The Financial Times stated that the acquisition of the California-based firm could be announced as early as Tuesday.
Danaher nears $10 bln deal to buy med tech firm Masimo- FT
U.S. healthcare firm Danaher Corp is reportedly close to a $10 billion deal to acquire medical technology company Masimo Corporation. The acquisition would value Masimo at a premium to its current market capitalization and could be announced as early as Tuesday. Masimo is known for manufacturing medical monitoring devices and has been involved in an intellectual property dispute with Apple Inc.
Danaher nears $10 bln deal to buy med tech firm Masimo- FT
U.S. healthcare firm Danaher Corp is reportedly close to a nearly $10 billion deal to acquire medical technology company Masimo Corporation. The Financial Times stated that an announcement could come as early as Tuesday. This acquisition would value Masimo at a premium to its current $7 billion market capitalization, continuing Danaher's aggressive history of dealmaking.
Danaher closes in on a nearly $10bn deal for med tech company Masimo - FT
Danaher Corporation is reportedly nearing a deal to acquire medical technology company Masimo for approximately $10 billion, according to a report by the Financial Times. This news follows several recent updates concerning Danaher, including a director's retirement and various analyst price target adjustments, indicating active financial and strategic movements for the company.
Vanguard Group Inc. Buys 124,481 Shares of Danaher Corporation $DHR
Vanguard Group Inc. increased its stake in Danaher Corporation by 0.2% in the third quarter, purchasing 124,481 additional shares to own a total of 60,894,068 shares valued at $12.07 billion. Danaher recently beat quarterly earnings expectations with $2.23 EPS and $6.84 billion in revenue. The stock, currently trading around $212.37, has a consensus "Moderate Buy" rating from analysts with an average target price of $253.86.
